Price war in insulin market? Novo Nordisk's price limit is euphemistic, and Lilly will be reduced by 40%

Source: medicine cube data: the problem of high drug prices on December 19, 2016 was unprecedented prominent and acute in 2016 Many companies were criticized by politicians and media as a typical example of malicious price increase, such as: a 60000 yuan, a 128% price increase, and another bad example of bid up drug prices appeared I'm wrong I'm right! Look at the wonderful logic of price increase of ariad pharmaceutical company! ·Increase price 600 times? Ergometrine will be listed in the national fixed-point purchase list! So when Brent Saunders, CEO of Elgin, made a statement three months ago that he would "limit the annual increase of the company's drug price to a single digit", it was like a clean stream flowing through the pharmaceutical industry On December 6, Novo Nordisk followed Elgin's steps and announced on the official website that it would limit the price increase of diabetes drugs in the company to no more than a single digit, so as to improve the accessibility of diabetes drugs and become the second large pharmaceutical enterprise to publicly limit the price increase of drugs Novo Nordisk's other planned measures to improve the accessibility of drugs include more price systems, including refund compensation, discount, CO payment, absolute deductible and co insurance, as well as various ways to reduce the proportion of patients' self payment In fact, after AI Erjian announced his drug price control plan, Pfizer CEO Ian read and regenerating yuan CEO Leonard Schleifer recently expressed their follow-up at a Forbes conference call Saunders expressed appreciation for Novo Nordisk's statement and called on other companies to take action on self-control of drug prices After the conscience of Novo Nordisk, Lilly, as the main competitor, offered a clearer price preference on December 13 From January 1, 2017, Lilly will cooperate with express s, the largest pharmacy welfare management agency in the United States, to provide insulin products with a price as low as 60% for diabetics without medical insurance coverage or with high absolute deductible Eligible patients who purchase Lilly's insulin products through blink health can enjoy the above discounts Lilly is also the first company to offer discounted original research drugs through blink health Lilly's products included in the discount plan include not only the old heavy bomb drugs Humalog and humlin, but also its Lantus analogue basaglar jointly developed with bringer Ingelheim Basaglar was approved by FDA as early as December 15, 2015 to improve blood glucose control in adults and children with type 1 diabetes and adults with type 2 diabetes However, because Sanofi filed a patent infringement lawsuit against Lilly / bringer, and finally reached a settlement, basaglar was not officially launched in the United States until December 15, 2016, but has missed the opportunity to enter the Medicare formulary Lilly allows up to 40% discount on the retail price of all insulin products, including basaglar It can be said that the price war is aimed at Sanofi and Novo Nordisk According to the prediction of evaluateparm, the American insulin market shrank by an average annual decrease of 2% With the launch of basaglar, Lilly may be the winner of the US insulin market in the next few years Compared with 2015, basaglar is expected to bring sales revenue of 774 million US dollars to Lilly by 2022; Novo Nordisk replaces Levemir with tresiba, which is a tortuous process, and is expected to bring sales revenue of 580 million US dollars; Sanofi is the worst, toujeo is difficult to continue to write Huihuang of Lantus, and is expected to reduce revenue by 2169 million US dollars Although the day trump won the election of the next president of the United States, the U.S biomedical stocks were all in the red, but the pressure of high drug prices faced by pharmaceutical companies was still increasing dramatically Trump, who was originally regarded as the spokesman of corporate interests, also changed his mind sharply in an interview with the times last week, saying that he would lower the price of drugs and trigger a wave of diving in pharmaceutical stocks Perhaps as Saunders, CEO of Elgin, said, "pharmaceutical companies should be aware of the importance of taking a positive attitude towards the self-control of drug prices Only in this way can pharmaceutical companies focus on the development of new therapeutic drugs to meet medical needs."